ARPC5L

Across TCGA pan-cancer cohorts, ARPC5L Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ARPC5L data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARPC5L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARPC5L expression acts as an unfavorable survival marker.

UCEC and PRAD are the cancer types where ARPC5L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.222	0.829	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ARPC5L–UCEC (OS)

Open the UCEC breakdown →